The use of Complementary and alternative medicines two years
Transcription
The use of Complementary and alternative medicines two years
The use of Complementary and alternative medicines two years after cancer diagnosis in France – evidence from the VICAN survey. Authors Objectives Aline Sarradon-Eck1,2, Anne-Déborah Bouhnik1,2, Dominique Rey1,2,3, Marc-Karim Bendiane1,2,3 Patrick Peretti-Watel1,2 and the VICAN group 1. INSERM, UMR912 «Economics and Social Sciences Applied to Health & Analysis of Medical Information» (SESSTIM), 13006, Marseille, France. 2. Aix Marseille University, UMR_S912, IRD, 13006, Marseille, France. 3. ORS PACA, Southeastern Health Regional Observatory, 13006, Marseille, France Background To evaluate the use of CAM in a representative sample of patients 2 years after a cancer diagnosis. To determine the profile of CAM-users in terms of : n nIncrease in the use of Complementary and alternative medicine (CAM), especially in the context of chronic diseases n nA growing number of studies focus on the use of CAM in cancer è èSocio-economic characteristics è èMedical characteristics è èSequelae n nEstimated rates of use varies according to countries and localisations (Molassiotis, 2005) : from 15% to 73% in Europe n nFew data in France : 34% (Trager-Maury, 2007) n nHowever, existing results need to be interpreted with caution, mainly due to recruitment bias Methods Results USE OF THE VICAN SURVEY (BOUHNIK ET AL, BMJ OPEN 2015) FACTORS ASSOCIATED WITH CAM USE n n16.4% of participants used CAM at time of the survey : »» 45,1% of them used CAM since diagnosis »» 66.0% reported only one type of CAM Socio-economic characteristics »» 22.2% reported 2 types of CAM »» 11.8% reported more than 2 types of CAM Gender Male Female Age <70 70 and more Social Deprivation Index Low Medium High Level of education <High school certificate ≥High school certificate Missing Types of CAM used (1/2) Alternative medical system Representative sample of patients, two years after cancer diagnosis. Objective : to describe life conditions of cancer survivors 12 localisations : breast cancer, prostate cancer, colorectal cancer, cervical cancer, endometrial cancer, melanoma, bladder cancer, kidney cancer, lung cancer, upper aerodigestive tract, non-Hodgkin lymphoma, thyroid cancer Selection of patients among individuals registered in one of the three main Health Insurance Schemes which together cover more than 90% of the French population. Data collected in 2012 / 4349 patients included (response rate=43.7%) Questions about CAM use : CAM use at time of the survey (yes/no) If yes, use of CAM before diagnosis (yes/no) and type of CAM used (open-question) Homeopathy Acupuncture Naturopathy Qi Gong Chinese medicine Tai Chi Isotherapy Manipulation and body-based methods Osteopathy Manipulative therapy Foot reflexology Auriculotherapy Etiopathy % Types of CAM used (2/2) % 75.5 Mind–body interventions 16.7 64.0 22.1 2.7 1.8 1.8 0.6 0.2 Energy therapy Magnetic healer Sophrology Yoga Hypnotherapy Biological decoding 5.8 4.1 3.5 1.4 1.0 0.9 19.7 15.1 2.2 2.0 0.6 0.5 Kinesiology Relaxation Meditation Shamanism Tibetan medicine Psychic therapies Akero therapies Biologically based therapies COMBINATION OF THREE SOURCES OF DATA Herbal medicine Diets Aromatherapy medical survey with the physician who iniated treatment Conclusions Paents-reported outcomes collected using the CATI system Estimation of CAM-use in a representative sample of patients, 2 years after diagnosis lower than what found in other surveys. 0.5 0.5 0.4 0.2 0.1 0.1 14.9 8.1 7.3 0.8 CI (95%) 1 2.7 2.2-3.2 1.5 1 1.4 1.2 1 p <.001 1.2-1.9 1.1-1.6 1.0-1.5 <.001 0.005 0.121 1 2.0 5.0 <.001 1.7-2.4 1.8-13.6 1 1.4 0.1 1.1-1.6 <0.1-1.0 0.001 0.048 1 1.3 1.3 1.0-1.5 0.4-5.0 0.013 0.655 Sequelae Fatigue clinically significant No Yes Missing Perceived pain No Yes Missing Acknowledgements Associated factors mainly related to socio-economic characteristics. members of the VICAN group : Thomas APARICIO, Emmanuel BABIN, François BECK, Robert BENAMOUZIG, Marc-Karim BEN DIANE, Cyril BERENGER, Dominique BESSETTE, Anne-Déborah BOUHNIK, Philippe-Jean BOUSQUET, Marie-Claude CABANELGICQUEL, Marianick CAVALLINI-LAMBERT, Michèle CHANTRY, Claire CHAUVET, Sébastien CORTAREDONA, Véronique DANGUY, Michel DORVAL, Jean-Baptiste HERBET, Laetitia HUIART, Xavier JOUTARD, Anne-Gaëlle LE CORROLLER-SORIANO, Julien MANCINI, Mégane MERESSE, Jean-François MORERE, Herman NABI, Alain PARAPONARIS, Patrick PERETTI-WATEL, Marie PREAU, Christel PROTIERE, Frédérique RETORNAZE, Dominique REY, Benoit RIANDEY, Luis SAGAON-TEYSSIER, Aurélia TISON, Valérie SEROR, Archana SINGH-MANOUX, Catherine THIEBLEMONT, Pierre VERGER. For nearly half of CAM-users, cancer was an initiating factor for using such medicines. This study was funded by The National Institute of Cancer (INCa),“Contrat de recherche et développement no 05-2011”. Types of CAM-use and associated factors similar to those encountered in the literature. Medico-administrave records including financial reimbursement data and hospital discharge records (SNIRR-AM database) 0.7 AOR Contact : [email protected]